Deutsche Bank Upgrades Amgen to “Buy”; Sees Strong Growth, Upside, and Higher Dividends Ahead (AMGN)

Biotech giant Amgen, Inc. (AMGN) late Monday received a big upgrade from analysts at Deutsche Bank.

The firm boosted its rating on AMGN from “Hold” to “Buy” while lifting its price target from $84 to $108.. That new target suggests a solid 23% upside to the stock’s Monday closing price of $87.80.

Deutsche Bank noted it believes the market is undervaluing the stock, given the company’s above-average growth. The firm commented, “Despite a recent move in shares, we continue to see upside as Amgen still trades at a discount to its pharma peers despite better ROE (28% vs 21%), EPS growth (14.8% vs. -0.3%). We think the co’s dividend will continue to grow closer to the pharma avg over the next 2 years (we model 35-40% dividend growth and a dividend yield of 3% by 2014-ABOVE consensus). Amgen also looks attractive from the biotech view, as the co trades at a 20-30% discount vs its biotech peers despite EPS growth that is only 10% lower than the group. ”

Amgen shares were mostly flat in premarket trading Tuesday.

The Bottom Line
Shares of Amgen, Inc. (AMGN) have a 1.64% dividend yield, based on last night’s closing stock price of $87.80. The stock has technical support in the $80-$82 price area. The shares are trading near all-time highs.

Amgen, Inc. (AMGN) is not recommended at this time, holding a DARS™ Rating of 3.4 out of 5 stars.

Be sure to visit our complete recommended list of the Best Dividend Stocks, as well as a detailed explanation of our ratings system here.

Related Stocks:
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here